MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 173 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Reply to C.D. Atkins
Daniel J. Sargent, Frank Sinicrope, Steven Gallinger
2010· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Final patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations receiving initial treatment with talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in the TALAPRO-2 study.
André P. Fay, Karim Fizazi, Nobuaki Matsubara, Arun Azad, Fred Saad, Ugo De Giorgi +12 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affaboutunlabeled
Impact of putative chemopreventative agents on prostate cancer diagnosis.
Hanan Goldberg, Faizan Moshin, Zachary Klaassen, Thenappan Chandrasekar, Christopher Wallis, Jaime O. Herrera‐Cáceres +8 more
2019· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in hepatocellular carcinoma: A systematic review and meta-analysis.
Isabella Romagnoli Buonopane, Erick Figueiredo Saldanha, Junior Samuel Alonso de Menezes, Renata D’Alpino Peixoto, Tiago Biachi De Castria, Camila Mariana de Paiva De Paiva Reis +2 more
2025· review· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About